Q&A
Patient Questions
Clear answers on diagnosis next steps, minimally invasive options, and insurance basics.
The five-year survival rate for advanced breast cancer is over 30%. With modern combination therapy — targeted drugs, immunotherapy, and minimally invasive options — there are more paths forward than ever before. Do not give up before a full multidisciplinary review.
For an untreated 1.5 cm tumor, do not delay — curative treatment is still achievable. Both surgical and non-surgical options exist; an MDT discussion will help decide the best path based on tumor biology and your preferences.
Yes. After complete resection, if radiotherapy is needed first, reconstruction is typically done about two years after surgery. Rectus abdominis muscle is usually preferred for a more natural contour; the final plan depends on your anatomy and opposite breast size.
Not necessarily. Not all patients need a stoma, and even when one is required it is not always permanent. Sphincter preservation is the priority whenever it is safe. The plan is tailored to the tumor location, disease stage and your overall health, so the most appropriate approach can differ considerably between two people with the same cancer name.
If a temporary stoma becomes part of the plan, it can often be reversed after healing. Understanding exactly why it is being proposed, and for how long, makes the decision far less frightening.
Mid-to-late stage cancer is not the same as terminal cancer. As treatment concepts and technology advance, some patients with advanced gastrointestinal cancer can still achieve long-term survival, even reaching a NED (no evidence of disease) state through standardized comprehensive treatment.
The realistic goal is set after reviewing complete staging and pathology: it may be cure, durable control, symptom relief, or time for a new therapy to become available. A late-stage diagnosis is not the end of the discussion.
Chemotherapy is no longer the only option. Depending on the tumor and stage, vascular intervention, ablation, seed implantation, targeted therapy and immunotherapy may play a leading or supporting role.
Precision minimally invasive treatments make a lower-chemotherapy or, in selected cases, chemo-free plan possible, aiming for high efficacy with lower toxicity. Whether they apply to you is decided after molecular testing and a multidisciplinary review, not from the cancer name alone.
Not necessarily. Early-stage patients who are healthy enough may undergo curative surgery. In mid-to-late stages, however, an immediate operation can sometimes cause more harm than benefit, and shrinking or stabilizing the tumor first may make later surgery safer, or unnecessary.
The order of treatment is a multidisciplinary decision based on stage, imaging and your fitness. Ask what each step is meant to achieve and what alternatives exist before committing to an operation date.
These are the questions young breast cancer patients are often most afraid to ask. Pregnancy does not automatically mean ending the pregnancy, and a cancer diagnosis does not automatically end the possibility of becoming a mother.
Care is planned trimester by trimester with obstetrics and neonatology when a patient is already pregnant. For those not yet pregnant, fertility counseling and, where appropriate, fertility preservation can be arranged before chemotherapy begins. Bring this concern to the first consultation rather than after treatment starts.
Hearing advanced, recurrence or metastasis often makes people feel it is over. It is not. Five-year survival for advanced breast cancer exceeds 30% overall, and individual results vary widely with subtype and treatment response.
Modern plans combine endocrine, targeted and immune therapy with local control of troublesome lesions, and can turn metastatic disease into a chronic, manageable condition for years. Re-testing biomarkers at recurrence is important, because a recurrent tumor may respond to drugs the original one did not.
